Successful perioperative management of living-donor liver transplantation for a patient with severe methylmalonic acidemia: a case report

Akiko Hirotsu 1*, Eriko Kusudo 2, Natsumi Mori 2, Yoshimitsu Miyai 1, Kengo Suzuki 1, Shuji Kawamoto 1 and Kazuhiko Fukuda 1

Abstract

Background: Methylmalonic acidemia (MMAemia) is a rare hereditary disease affecting organic acid metabolism. It causes recurrent metabolic acidosis and secondary mitochondrial dysfunction, resulting in a poor prognosis. Liver transplantation (LT) has been performed to facilitate the metabolism of organic acids and improve the prognosis of MMAemia. However, there have been few reports on perioperative management of LT.

Case presentation: A 22-month-old female with severe MMAemia was scheduled to receive LT to relieve recurrent metabolic acidosis despite dietary and pharmacological treatment. General anesthesia was maintained without propofol or nitrous oxide, which can worsen MMAemia-induced metabolic acidosis during anesthesia for LT. Strict metabolic and respiratory management enabled the operation to be successfully performed without metabolic acidosis.

Conclusion: Perioperative management of LT for MMAemia is challenging for anesthesiologists because of the possibility of serious metabolic acidosis. We succeeded in preventing metabolic decompensation by avoiding the use of propofol and nitrous oxide.

Keywords: Methylmalonic acidemia, Liver transplantation, Metabolic acidosis, Perioperative management

Background

Methylmalonic acidemia (MMAemia) is a rare hereditary disease caused by the accumulation of methylmalonic acid (MMA) due to metabolic disorders related to methylmalonyl-CoA mutase (MCM) or vitamin B12, the co-enzyme of MCM [1]. MMAemia can affect multiple organ systems, including the liver, kidney, and central nervous system, and the patient often suffers from vomiting, seizures, developmental retardation, and metabolic acidosis. Dietary and pharmacological treatment should be started as soon as the patient is diagnosed with MMAemia because several amino acids, odd-chain fatty acids, and some intestinal flora can facilitate MMA accumulation (Fig. 1).

However, the patient often suffers from life-threatening metabolic acidosis requiring emergency treatment characterized by vomiting and elevated ammonia (NH3), following hypercatabolism due to febrile illness and inappropriate nutrition [2]. In 50% of severe cases, the patient does not survive beyond 3 years of age because of severe metabolic acidosis and its related symptoms. Recently, liver transplantation (LT) has been performed as supportive therapy for children with severe MMAemia to improve MMA metabolism through the action of the transplanted healthy liver [3]. However, there are few reports on perioperative management of LT for MMAemia [4].

Case presentation

A 22-month-old female (70 cm, 9.9 kg) with MMAemia was admitted to our hospital to receive living donor LT (LDLT) from her mother. Three days after her normal
birth, metabolic acidosis and seizures appeared, and genetic tests revealed a MCM defect, which is one of the most common types of abnormalities in Japanese people. Despite a protein-restricted diet, vitamin B₁₂ and l-carnitine supplements, and treatment with anticonvulsant agents, her symptoms were poorly controlled. She was transferred to our hospital with continuous infusion of glucose, vitamin B₁₂, and l-carnitine. Her preoperative arterial blood gas (ABG) data were within normal ranges (Table 1). Preoperative plasma MMA (P-MMA) was 157 nmol/ml (normal range 0.35 ± 0.22 nmol/ml). Hepatic and renal functions were within the normal ranges.

On the day of the operation, after fasting for 6 h, the patient was transferred to the operating room with continuous glucose, vitamin B₁₂, and l-carnitine infusion. General anesthesia was induced and maintained with sevoflurane, fentanyl, remifentanil, and rocuronium. After tracheal intubation, a catheter for continuous hemodiafiltration (CHDF) was inserted to facilitate further intraoperative treatment of metabolic acidosis. Although metabolic acidosis with elevated lactate and NH₃ occurred during the anhepatic phase, all improved promptly after graft reperfusion (Table 1). LDLT was completed without the use of CHDF or sodium bicarbonate administration for metabolic acidosis. The operation time and anesthetic time were 9 h 45 min and 12 h 40 min, respectively. The total fluid infusion was 1175 ml, including transfusion of 1 unit of red blood cells and 1 unit of fresh frozen plasma. Total urine output was 135 ml, and a small amount of bleeding occurred.

The patient was transferred to the ICU under sedation with midazolam. She was extubated on postoperative day (POD) 3, and P-MMA improved to 18.7 nmol/ml on POD 7. She was discharged on POD 80.

**Discussion**

The guidelines for diagnosis and management of MMAemia suggest that LT should be considered in

---

**Table 1** Preoperative and intraoperative arterial blood gas data. Normal range of ammonia (NH₃) is 20–60 μg/dl

|                      | Pre-operation | At the time of operation | Before reperfusion | 2 h after reperfusion | End of operation |
|----------------------|---------------|-------------------------|--------------------|-----------------------|-----------------|
| pH                   | 7.373         | 7.377                   | 7.231              | 7.332                 | 7.344           |
| PaCO₂ (mmHg)         | 42            | 34.4                    | 35.6               | 29.6                  | 33.3            |
| HCO₃ (mmol/l)        | 23.9          | 19.8                    | 14.6               | 15.3                  | 17.7            |
| Base excess          | −1.3          | −4.8                    | −11.9              | −9.4                  | −7.1            |
| Lactate (mg/dl)      | 23.8          | 53.2                    | 54.3               | 30                    | 33              |
| NH₃ (μg/dl)          | 55            | 48                      | 139                | 58                    | 52              |
| Glucose (mg/dl)      | 132           | 173                     | 192                | 200                   | 237             |

---

**Fig. 1** Metabolic pathway of methylmalonic acidemia. Methylmalonic acid (MMA) accumulates systemically because of intracellular methylmalonyl-CoA mutase (MCM) or vitamin B₁₂, the coenzyme of MCM.
patients with MMAemia who suffer frequent metabolic acidosis despite dietary and medical treatment [1]. A report on 14 cases of LT for MMAemia in a single institute in Japan showed that severe metabolic acidosis occurred in 3 cases at the start of the operation, and death occurred perioperatively in 2 of these 3 cases [4]. Thus, metabolic acidosis should be prevented during LT, even though the prognosis of MMAemia after LT has recently been improved [4].

In a patient with MMAemia, MMA accumulation can cause metabolic acidosis and secondary mitochondrial dysfunction. In contrast to the normal situation, in which the tricarboxylic acid (TCA) cycle is supplied with glucose and succinyl-CoA, in MMAemia succinyl-CoA deficiency causes operation of the TCA cycle to depend mostly on glucose, leading to adenosine triphosphate (ATP) deficiency. Lactate tends to accumulate, followed by lactate acidosis, because the ATP deficiency is compensated by conversion of pyruvate to lactate under anaerobic conditions. NH3 can also accumulate because the urea cycle, an ATP consumption pathway in hepatic cells, cannot efficiently process urea. To make matters worse, anaerobic metabolism in the liver graft during the anhepatic phase of LT and the following ischemic graft reperfusion can facilitate metabolic acidosis. In contrast, carnitine plays a beneficial role in patients with MMAemia by binding to propionyl-CoA in liver cells, which facilitates its excretion as propionylcarnitine and prevents accumulation of MMA [5].

We took the pathophysiology of MMAemia into consideration in planning for perioperative management of LT. First, we continued supplementation of glucose, vitamin B12, and L-carnitine. Second, we prepared for CHDF to facilitate treatment of metabolic acidosis as needed. Finally, we avoided the use of nitrous oxide (N2O) and propofol. N2O inhibits adenosyl cobalamin, the cofactor of MCM, through irreversible oxidation of cobalt atoms in vitamin B12, and can increase MMA accumulation in patients with MMAemia [6]. Propofol may not harm the patient with MMAemia, considering that the metabolites of propofol and its emulsion are not turning into the precursor of MMA [7], and a previous report had described the effectiveness and safety of the brief use of propofol [8]. However, propofol can inhibit the mitochondrial electron transport system and coupling of oxidative phosphorylation [9] and can exacerbate mitochondrial dysfunction in MMAemia. Furthermore, prolonged and high-dose propofol administration can cause propofol infusion syndrome, characterized by metabolic acidosis, rhabdomyolysis, and liver failure. Although our management could prevent acidosis during LT, further investigation is required for the establishment of safe perioperative management of the patients with MMAemia [9].

The long-term prognosis of MMAemia after LT is unclear because compromised mitochondrial function in renal cells can cause future renal failure [10]. Besides, in LDLT, MCM activity in a graft from a related donor might be lower than that of a non-related donor due to the heterozygous abnormality in the related donor. Thus, long-term observation is needed in these cases.

Conclusion

Perioperative management of LT for MMAemia is challenging for anesthesiologists because serious metabolic acidosis can occur. We successfully prevented metabolic acidosis in the perioperative period by cautious planning for management of the patient based on the pathophysiology of MMAemia.

Abbreviations

ABG: Arterial blood gas; ATP: Adenosine triphosphate; CHDF: Continuous hemodiafiltration; LDLT: Living donor LT; LT: Liver transplantation; MCM: Methylmalonyl-CoA mutase; MMA: Methylmalonic acid; MMAemia: Methylmalonic acidemia; N2O: Nitrous oxide; NH3: Ammonia; P-MMA: Plasma MMA; POD: Postoperative day; TCA: Tricarboxylic acid

Acknowledgements
We would like to thank PALABRA (https://www.palabra.co.jp) for English language editing.

Funding

The authors declare no conflicts of interest associated with this manuscript.

Availability of data and materials

All data generated or analyzed in this study are included in this article.

Authors’ contributions

AH wrote the initial draft of the manuscript. NM and YM performed perioperative management. EK, KS, and SK were attending anesthesiologists for the case. SK supervised the perioperative management and helped to draft the manuscript. KF supervised and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written consent was obtained from the parent of the patient for publication of this case report.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Department of Anesthesia, Kyoto University Hospital, Shogoin-kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. 2. Department of Anesthesia, Osaka Red Cross Hospital, 5-30, Fudegasaki-cho, Tennoji-ku, Osaka 543-8555, Japan.
References

1. Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014. https://doi.org/10.1186/s13023-014-0130-8.

2. Zwicker T, Haege G, Riderer A, et al. Metabolic decompensation in methylmalonic aciduria: which biochemical parameters are discriminative? J Inherit Metab Dis. 2012;35:797–806.

3. Spada M, Calvo PL, Brunati A, et al. Early liver transplantation for neonatal-onset methylmalonic acidemia. Pediatrics. 2015;136:e252–6.

4. Baba C, Kasahara M, Kogure Y, et al. Perioperative management of living-donor liver transplantation for methylmalonic acidemia. Pediatr Anesth. 2016;26:694–702.

5. Chalmers RA, Roe CR, Stacey TE, Hoppel CE. Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine. Pediatr Res. 1994;18:1325–8.

6. Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109:707–22.

7. Court MH, Duan SX, Hesse LM, et al. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology. 2001;94:110–9.

8. Khalsa KP, Ramstad T, Baker EH, et al. Propofol administration in patients with methylmalonic acidemia and intracellular cobalamin metabolism disorders: a review of theoretical concerns and clinical experiences in 28 patients. J Inherit Metab Dis. 2015;38:47–53.

9. Julie N, Phil GM. Anesthetic considerations in patients with mitochondrial defects. Paediatr Anaesth. 2013;23:785–93.

10. Zsengeller ZK, Aljinovic N, Teot LA, et al. Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol. 2014;29:2139–46.